Compare Gilead Sciences, Inc. (GILD) vs Vanguard High Dividend Yield ETF (VYM) Price & Performance

Gilead Sciences, Inc.Trade

Vanguard High Dividend Yield ETFTrade

Price performance (Past 24H)

Key statistics

Gilead Sciences, Inc. vs Vanguard High Dividend Yield ETF — how do they compare? Gilead Sciences, Inc. trades at $135 (market cap $164.99B), while Vanguard High Dividend Yield ETF trades at $166.68. The key difference: Gilead Sciences, Inc. pays a 2.47% dividend while Vanguard High Dividend Yield ETF pays none, and Vanguard High Dividend Yield ETF is trading nearer its 52-week high, Gilead Sciences, Inc. nearer its low. Which is the better fit depends on your goals.

	GILD	VYM
Market Cap	$164.99B	—
Sector	Health	—
52-Week High	$155.80	$166.14
52-Week Low	$110.56	$136.63
Enterprise Value	$188.06B	—
Dividend Yield	2.47%	—

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Gilead Sciences, Inc.

No Aura AI signal available yet.

Vanguard High Dividend Yield ETF

VYM trades at $165.63, up 0.52% today, near its 52-week high with strong bullish momentum from moving averages. The ETF's technicals show overbought RSI signals but positive ADX trends, while recent news highlights its role in retirement income strategies. A dividend of $0.98 is scheduled for June 2026, reinforcing its income focus amid institutional adjustments.

Outlook remains positive for income-seeking investors due to VYM's dividend reliability and sector diversification, though overbought conditions and underperformance versus the S&P 500 pose risks. Key opportunities include sustainable yield; risks involve market volatility and interest rate sensitivity.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

GILD

Gilead upgrades 2026 sales outlook as HIV drug Biktarvy and Livdelzi show strong growthSeeking Alpha · 2 days agoBullish 2026 National ORBIE Awards honor top CIOs and CISOs across key industry categories in San Jose.Inspire Leadership Network · 4 days agoNeutral View details →

VYM

SCHD ETF's index reshuffle caused unexpected high taxable distributions in 2024, hitting taxable accounts hard.24/7 Wall Street · 15 hours agoNeutral Vanguard High Dividend Yield ETF lags S&P 500 by $141K over 10 years despite dividends.24/7 Wall Street · 1 day agoBearish WisdomTree U.S. Total Dividend ETF (DTD) rated 'hold' for balanced factors but overlaps 57% with S&P 500 ETFs.Seeking Alpha · 1 day agoNeutral View details →

About Gilead Sciences, Inc.

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.

About Vanguard High Dividend Yield ETF

The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that pay dividends that generally are higher than average. The advisor attempts to replicate the target index by investing all, or substantially all, of the fund's assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.